Single-dose, open-label, randomized, 2-way crossover bioequivalence study of 10 mg granules for oral suspension rivaroxaban versus 10 mg tablets rivaroxaban under fasted condition in healthy subjects

Trial Profile

Single-dose, open-label, randomized, 2-way crossover bioequivalence study of 10 mg granules for oral suspension rivaroxaban versus 10 mg tablets rivaroxaban under fasted condition in healthy subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 11 Nov 2017

At a glance

  • Drugs Rivaroxaban (Primary)
  • Indications Venous thrombosis
  • Focus Pharmacokinetics
  • Sponsors Bayer
  • Most Recent Events

    • 09 Nov 2017 Status changed from recruiting to completed.
    • 28 Jun 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top